Jeffrey Cohen

4.8k total citations · 2 hit papers
52 papers, 3.0k citations indexed

About

Jeffrey Cohen is a scholar working on Pathology and Forensic Medicine, Rheumatology and Oncology. According to data from OpenAlex, Jeffrey Cohen has authored 52 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pathology and Forensic Medicine, 16 papers in Rheumatology and 11 papers in Oncology. Recurrent topics in Jeffrey Cohen's work include Multiple Sclerosis Research Studies (37 papers), Rheumatoid Arthritis Research and Therapies (12 papers) and Peripheral Neuropathies and Disorders (8 papers). Jeffrey Cohen is often cited by papers focused on Multiple Sclerosis Research Studies (37 papers), Rheumatoid Arthritis Research and Therapies (12 papers) and Peripheral Neuropathies and Disorders (8 papers). Jeffrey Cohen collaborates with scholars based in United States, United Kingdom and Czechia. Jeffrey Cohen's co-authors include Eva Havrdová, Douglas L. Arnold, Krzysztof Selmaj, Alasdair Coles, David Margolin, D. A. S. Compston, Michael Panzara, Edward Fox, Hans-Peter Hartung and Howard L. Weiner and has published in prestigious journals such as The Lancet, Neurology and Annals of Neurology.

In The Last Decade

Jeffrey Cohen

49 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

2012 884 citations Alasdair Coles, Cary Twyman et al. The Lancet profile →
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

2012 883 citations Jeffrey Cohen, Alasdair Coles et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Cohen United States	16	2.4k	924	776	709	701	52	3.0k
Vesna Brinar Croatia	22	2.6k 1.1×	1.2k 1.3×	600 0.8×	781 1.1×	576 0.8×	99	3.5k
J. A. Cohen United States	13	2.5k 1.0×	1.2k 1.3×	523 0.7×	792 1.1×	591 0.8×	23	3.0k
J. S. Wolinsky United States	19	2.8k 1.2×	1.4k 1.5×	600 0.8×	922 1.3×	755 1.1×	38	3.4k
Gavin Giovannoni United Kingdom	26	3.0k 1.2×	1.1k 1.1×	1.2k 1.6×	798 1.1×	944 1.3×	63	3.7k
Benjamin Brooks United States	9	1.9k 0.8×	958 1.0×	451 0.6×	653 0.9×	577 0.8×	14	2.3k
Dusan Stefoski United States	24	1.7k 0.7×	641 0.7×	592 0.8×	456 0.6×	543 0.8×	56	2.7k
Ludwig Kappos Switzerland	2	1.9k 0.8×	607 0.7×	924 1.2×	411 0.6×	660 0.9×	2	2.5k
Martin Toal United States	6	1.9k 0.8×	600 0.6×	977 1.3×	417 0.6×	685 1.0×	9	2.6k
Marcelo Kremenchutzky Canada	23	2.3k 0.9×	944 1.0×	437 0.6×	735 1.0×	295 0.4×	64	2.9k
HP Hartung Germany	18	1.8k 0.8×	1.1k 1.2×	469 0.6×	721 1.0×	325 0.5×	58	2.3k

Countries citing papers authored by Jeffrey Cohen

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Cohen more than expected).

Fields of papers citing papers by Jeffrey Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Cohen. The network helps show where Jeffrey Cohen may publish in the future.

Co-authorship network of co-authors of Jeffrey Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Cohen. A scholar is included among the top collaborators of Jeffrey Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Cohen. Jeffrey Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Jeffrey, et al.. (2025). Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis. Brain and Behavior. 15(3). e70310–e70310.

Cohen, Jeffrey, et al.. (2024). Ongoing randomized clinical trials on HSCT in multiple sclerosis. Handbook of clinical neurology. 202. 307–315. 2 indexed citations

Li, Yadi, Brittany Lapin, Le H. Hua, et al.. (2024). Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors. Annals of Clinical and Translational Neurology. 12(3). 643–647.

Fox, Edward, David Brassat, Raed Alroughani, et al.. (2017). Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) (S24.006). Neurology. 88(16_supplement). 2 indexed citations

Cadavid, Diego, Jeffrey Cohen, Mark S. Freedman, et al.. (2016). The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Multiple Sclerosis Journal. 23(1). 94–105. 98 indexed citations

Coles, Alasdair, Douglas L. Arnold, Jeffrey Cohen, et al.. (2016). Patients with Active RRMS and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study (P3.022). Neurology. 86(16_supplement). 5 indexed citations

Cohen, Jeffrey, Douglas L. Arnold, Alasdair Coles, et al.. (2015). Slowing of Brain Volume Loss in Patients With Relapsing-Remitting Multiple Sclerosis After Switching From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.264). Neurology. 84(14_supplement). 2 indexed citations

LaGanke, Christopher, Regina Berkovich, Jeffrey Cohen, et al.. (2015). Durable Effect of Alemtuzumab on Disability Improvement in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P3.261). Neurology. 84(14_supplement). 2 indexed citations

Arnold, Douglas L., Anthony Traboulsee, Alasdair Coles, et al.. (2015). Durable Effect of Alemtuzumab on MRI Activity in Treatment-Naive Active Relapsing-Remitting Multiple Sclerosis Patients: 4-Year Follow-up of CARE-MS I (P7.246). Neurology. 84(14_supplement). 6 indexed citations

10.

Henson, Lily Jung, Douglas L. Arnold, Jeffrey Cohen, et al.. (2015). Incidence of Infection Decreases Over Time in Alemtuzumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 4-Year Follow-up of the CARE-MS Studies (P7.265). Neurology. 84(14_supplement). 5 indexed citations

11.

Hersh, Carrie M. & Jeffrey Cohen. (2014). Alemtuzumab for the Treatment of Relapsing–Remitting Multiple Sclerosis. Immunotherapy. 6(3). 249–259. 17 indexed citations

12.

Hartung, Hans, Timothy Vollmer, Douglas L. Arnold, et al.. (2013). Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093). Neurology. 80(7_supplement). 2 indexed citations

13.

Giovannoni, Gavin, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120). Neurology. 80(7_supplement). 1 indexed citations

14.

Wray, Sibyl, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172). Neurology. 80(7_supplement). 1 indexed citations

15.

LaGanke, Christopher, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174). Neurology. 80(7_supplement). 3 indexed citations

16.

Fox, Edward, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001). Neurology. 80(7_supplement). 11 indexed citations

17.

Cohen, Jeffrey, Alasdair Coles, Douglas L. Arnold, et al.. (2012). Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet. 380(9856). 1819–1828. 883 indexed citations breakdown →

18.

Goldman, Myla, Jeffrey Cohen, Robert J. Fox, & François Béthoux. (2006). Multiple sclerosis: treating symptoms, and other general medical issues.. Cleveland Clinic Journal of Medicine. 73(2). 177–186. 15 indexed citations

19.

Cohen, Jeffrey. (2001). Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial. Archives of Neurology. 58(6). 961–961. 141 indexed citations

20.

Cohen, Jeffrey, et al.. (1999). Sumatriptan treatment for migraine in a health maintenance organization: Economic, humanistic, and clinical outcomes. Clinical Therapeutics. 21(1). 190–204. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact